ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 37,500 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $40.91, for a total value of $1,534,125.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Glenn Baity also recently made the following trade(s):

  • On Wednesday, August 30th, Glenn Baity sold 26,507 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $34.87, for a total value of $924,299.09.
  • On Wednesday, August 9th, Glenn Baity sold 14,322 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $34.88, for a total value of $499,551.36.
  • On Thursday, July 20th, Glenn Baity sold 38,097 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $30.00, for a total value of $1,142,910.00.

ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) opened at 38.54 on Friday. ACADIA Pharmaceuticals Inc. has a 52-week low of $20.68 and a 52-week high of $41.20. The firm’s market cap is $4.72 billion. The firm’s 50-day moving average price is $36.00 and its 200 day moving average price is $31.68.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.17. The company had revenue of $30.50 million for the quarter, compared to analysts’ expectations of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The business’s revenue for the quarter was up 30400.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.63) earnings per share. On average, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.53) earnings per share for the current year.

WARNING: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/glenn-baity-sells-37500-shares-of-acadia-pharmaceuticals-inc-acad-stock/1616800.html.

Several analysts have commented on the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $61.00 price objective (up from $54.00) on shares of ACADIA Pharmaceuticals in a research note on Thursday. JMP Securities upped their price objective on ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday. Bank of America Corporation upped their price objective on ACADIA Pharmaceuticals from $40.00 to $46.00 and gave the company a “positive” rating in a research note on Thursday. Finally, J P Morgan Chase & Co set a $50.00 price objective on ACADIA Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. ACADIA Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $46.21.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACAD. Nationwide Fund Advisors bought a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $424,000. Russell Investments Group Ltd. raised its holdings in shares of ACADIA Pharmaceuticals by 379.7% during the first quarter. Russell Investments Group Ltd. now owns 24,150 shares of the biopharmaceutical company’s stock valued at $831,000 after buying an additional 19,116 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of ACADIA Pharmaceuticals by 7.6% during the first quarter. Wells Fargo & Company MN now owns 135,888 shares of the biopharmaceutical company’s stock valued at $4,672,000 after buying an additional 9,608 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 27.2% during the first quarter. American Century Companies Inc. now owns 16,873 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 3,610 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of ACADIA Pharmaceuticals by 5.6% during the first quarter. Bank of New York Mellon Corp now owns 396,646 shares of the biopharmaceutical company’s stock valued at $13,636,000 after buying an additional 21,191 shares during the last quarter. 97.10% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.